Internal Medicine, Hematology & Oncology · Chattanooga, TN
NPI
1205996014
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
605 Glenwood Drive, Suite 200
Chattanooga, TN, 37404
Phone (423) 698-1844
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.7M
343,400 services
Medicare patients, 2024
1,041
Average age 74
Drug cost, 2024
$11.5M
3,134 prescriptions
Company payments, 2025
$2,314
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bertrand M Anz III was code J9025 (injection, azacitidine, 1 mg), 45,600 times for 14 patients. In total Bertrand M Anz III billed 343,400 services in 222 codes, and Medicare paid $6.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-10-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9025 Injection, azacitidine, 1 mg | Office | 45,600 | 14 | $0.30 | $14K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 27,275 | 220 | $0.10 | $2,739 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 24,600 | 24 | $44.78 | $1.1M |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 22,140 | 15 | $39.24 | $869K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 18,860 | 20 | $2.30 | $43K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 13,200 | 25 | $0.11 | $1,431 |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 12,000 | 11 | $0.80 | $9,635 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 5,112 | 15 | $36.74 | $188K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 5,100 | 44 | $15.96 | $81K |
| J0897 Injection, denosumab, 1 mg | Office | 4,020 | 24 | $20.31 | $82K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,675 | 86 | $0.09 | $328 |
| 85025 Blood Count | Office | 2,989 | 561 | $7.50 | $22K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2,460 | 11 | $31.69 | $78K |
| 36415 Venipuncture Blood Collection | Office | 2,169 | 522 | $8.53 | $19K |
| 80053 Clinical Chemistry | Office | 2,081 | 496 | $10.19 | $21K |
By year: 2022 $4.2M for 266,032 services; 2023 $5.2M for 309,624 services; 2024 $6.7M for 343,400 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,989 | 561 | $7.50 | $22K |
| 36415 Venipuncture Blood Collection | 2,169 | 522 | $8.53 | $19K |
| 80053 Clinical Chemistry | 2,081 | 496 | $10.19 | $21K |
| 82784 Immunoassay | 793 | 84 | $9.04 | $7,170 |
| 83615 Clinical Chemistry | 578 | 175 | $5.87 | $3,392 |
| 83521 Immunoassay | 507 | 81 | $16.92 | $8,581 |
| 84165 Clinical Chemistry | 295 | 112 | $10.38 | $3,063 |
| 82728 Clinical Chemistry | 280 | 172 | $13.00 | $3,640 |
| 86334 Immunoassay | 279 | 105 | $21.56 | $6,017 |
| 83540 Clinical Chemistry | 271 | 170 | $6.14 | $1,665 |
Medicare prescription drug claims, 2024
In 2024, the drug Bertrand M Anz III prescribed most often to Medicare patients was Prednisone, with 204 prescriptions and refills. In total Bertrand M Anz III wrote 3,134 Medicare prescriptions that cost $11.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 204 | 277 | 63 | $1,289 |
| Acyclovir Generic | 200 | 303 | 52 | $3,883 |
| Eliquis Apixaban | 167 | 227 | 43 | $132K |
| Ondansetron Odt Ondansetron | 156 | 158 | 77 | $1,773 |
| Abiraterone Acetate Generic | 111 | 111 | 19 | $320K |
| Revlimid Lenalidomide | 105 | 105 | 16 | $1.8M |
| Jakafi Ruxolitinib Phosphate | 99 | 99 | 12 | $1.4M |
| Venclexta Venetoclax | 93 | 93 | 20 | $447K |
| Anastrozole Generic | 86 | 236 | 31 | $1,606 |
| Dexamethasone Generic | 83 | 94 | 33 | $1,345 |
| Brukinsa Zanubrutinib | 73 | 73 | 12 | $893K |
| Prochlorperazine Maleate Generic | 69 | 69 | 51 | $869 |
| Folic Acid Generic | 55 | 100 | 16 | $189 |
| Levothyroxine Sodium Generic | 47 | 97 | 13 | $519 |
| Potassium Chloride Generic | 47 | 77 | 21 | $685 |
Brand drugs: 1,024 claims; generic drugs: 2,110 claims; opioid claims: 121.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bertrand M Anz III $2,314 ($867 in general payments such as food, travel and fees and $1,447 for research) from 22 companies. The largest payer was F. Hoffmann-La Roche AG with $1,447.
| Company | Payments | Amount |
|---|---|---|
| F. Hoffmann-La Roche AG ROG.SW | 2 | $1,447 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $239 |
| Kite Pharma, Inc. GILD | 1 | $111 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $74.09 |
| Gilead Sciences, Inc. GILD | 3 | $74.04 |
| Adc Therapeutics America, Inc. | 3 | $57.49 |
| Incyte Corporation INCY | 2 | $50.73 |
| Astellas Pharma US Inc 4503.T | 2 | $48.18 |
| Exelixis Inc. EXEL | 1 | $28.14 |
| Celgene Corporation BMY | 1 | $27.45 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.